



ASX Release

25 August 2017

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
Web: www.zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

ASX Code:

ZLD

Ordinary Shares:

754,841,934

Options:

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -
subject to vesting conditions)
2,000,000 (\$0.04 - 6/2/2020)
40,000,000 (\$0.03125-17/11/2021)

COMPANY PRESENTATION ON 2017 HALF YEAR ACTIVITIES

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** advises that its financial statements are scheduled for release to the ASX on Wednesday 30 August 2017.

Dr. Stewart Washer has recorded an update of the Company's activities since completing the compliance and re-listing on 18 November 2016 to 30 June 2017.

Investors and interested parties can access the update via the URL: <http://www.zeldatherapeutics.com/>

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda's*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a programme of human clinical trials initially in sleep disorder (insomnia), autism and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.